Entecavir: 8 agencies, 2006–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Treatment of chronic hepatitis B virus infection in: adults with decompensated liver disease; nucleoside naive paediatri…”, while SMC (Scotland) recorded not recommended for “Treatment of chronic hepatitis B infection in adults with decompensated liver disease”.
The file has been open for more than a decade: 15.9 years separate the first record, 1 Nov 2006 at TLV (Sweden), from the most recent, 27 Oct 2022 at CIPM (Spain).
PHARMAC (New Zealand) changed its position: not recommended on 2 Aug 2012, recommended by 9 Feb 2017, after a resubmission.
No assessment is on file from PBAC (Australia) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for entecavir, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
5 distinct indication wordings are recorded for entecavir by the agencies that label one in English (AWMSG, NICE and SMC).
TLV (Sweden) was first to assess entecavir, on 1 Nov 2006; CIPM (Spain) did not open a file until 27 Oct 2022 — an unusually long tail of 15.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 8 agencies here assessed entecavir more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for entecavir.
The full ledger for entecavir reads 6 recommended, 3 other, 2 not recommended and 1 withdrawn, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 27 Oct 2022 | Indicación terapéutica autorizada : Entecavir Mylan está indicado para el tratamiento de la infección crónica por el vir… | excluded from SNS provision · art. 92 e | source |
| HAS (France) | 4 Apr 2018 | Listing renewal (Transparency Committee) | SMR substantial | source |
| CONITEC (Brazil) | 7 Dec 2016 | Tratamento da hepatite crônica viral B sem agente delta, compatibilizando o código B18.1 da CID10 com os respectivos pro… | incorporated into SUS | source |
| PHARMAC (New Zealand) | 2 Aug 2012 | Hospital listing | PTAC advice: Not recommended for inclusion (HML) · decision reached | source |
| AWMSG (Wales) | 7 Mar 2007 | Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and evidence of active v… | excluded, NICE appraised | source |
9 further decisions for entecavir, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 14 decisions for entecavir from 8 agencies, 2006 to 2022. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.